Periodontal disease and periodontal bacteria as triggers for rheumatoid arthritis

Zijian Cheng¹, Josephine Meade¹, Kulveer Mankia², Paul Emery², Deirdre Devine¹*

1. Division of Oral Biology, School of Dentistry, University of Leeds, UK.
2. Leeds Musculoskeletal Biomedical Research Unit, School of Medicine, University of Leeds, UK

* Corresponding author. Tel.: +44 (0) 113 343 6116/6159, Fax: +44 (0) 113 343 6548
E-mail address: d.a.devine@leeds.ac.uk (D. Devine)
Abstract

There is an epidemiological association between periodontitis and rheumatoid arthritis (RA), hypothesised to lead to enhanced generation of RA-related autoantibodies, which can be detected years before the onset of RA symptoms. Periodontitis is a common dysbiotic disease; tissue damage occurs because the immune system fails to limit both the resident microbial community and the associated local immune response. Certain periodontal bacteria, including Porphyromonas gingivalis and Aggregatibacter actinomycetemcomitans, may contribute to RA-autoantibody production through direct post-translational modification of proteins or, indirectly, by influencing neutrophil-mediated neo-epitope generation. Oral bacteria that invade the blood may also contribute to chronic inflammatory responses and generation of autoantibodies. The putative association between periodontitis and the development of RA raises the potential of finding novel predictive markers of disease and disease progression, and for periodontitis treatment to be included in the future as an adjunct to conventional RA immunotherapy or as part of a preventive strategy.

Keywords

Rheumatoid arthritis; Periodontitis; Autoantibody; Subgingival microbiome; Porphyromonas gingivalis
Introduction

Rheumatoid arthritis (RA) is a systemic autoimmune disease that manifests as a chronic polyarthritis. There is increasing evidence that the initiating events that result in the generation of RA-related autoantibodies, which can be detected years before the onset of RA symptoms, occur at mucosal sites distant to the joints [1-5]. Inflammatory processes in response to environmental triggers, including infections, in the lungs and the mouth have been strongly implicated and, recently, also in the gastrointestinal and genitourinary tracts [4-7]. This review concentrates on the contribution of oral disease, specifically periodontal disease, and oral bacteria to the development of RA.

Periodontal diseases are common oral inflammatory conditions that occur in response to bacterial plaque biofilms, causing damage to the gingivae (gums), periodontal ligament and alveolar bone, all of which form the supporting tissues of the teeth (Figure). Severe periodontitis occurs in 2-20% of most adult populations, affecting 300 million people worldwide [8]. In the UK, 3-4 million currently suffer from advanced periodontitis at a cost of £2 billion/year to the National Health Service (NHS). Associations have emerged between periodontitis and a growing list of chronic conditions including atherosclerosis, diabetes and RA [9-11].

The links between rheumatoid arthritis and periodontal disease.

RA and periodontitis display some pathogenic similarities, such as the host immune response leading to soft tissue inflammation with subsequent hard tissue destruction, and certain risk factors, including smoking and excess weight or obesity, although some studies only show associations at specific stages of disease aetiology [12-17]. The significant RA risk attributed to the shared epitope HLA-DRβ1 (SE) is well established [18], but associations of specific human leukocyte antigen (HLA) molecules with chronic periodontitis are unclear.
Multiple studies have shown an epidemiological association between periodontitis and RA and these have been reviewed recently [6, 19, 20]. Inconsistent diagnosis of periodontal disease may have led to an alternative conclusion in some studies [6, 21]. However, a systematic review and meta-analysis confirmed an elevated risk of periodontitis in RA patients compared with healthy controls [19]. Analyses of detailed clinical data have revealed significantly raised indicators of the severity of periodontal disease (mean probing depth; bleeding on probing, BOP; absolute clinical attachment loss, CAL; tooth loss) in people with RA compared to those without [19, 22].

Understanding the common mechanisms that underlie periodontitis and RA could present new possibilities for the treatment and prevention of RA. The link between these conditions was further highlighted in a recent study where patients with periodontitis and arthralgia who later developed RA had higher levels of disease activity and were more likely to receive methotrexate at RA diagnosis compared to patients without periodontitis [23].

**Periodontal diseases**

Periodontal diseases are complex polymicrobial conditions resulting from an imbalance between the resident subgingival microbial communities, which grow as biofilms adhered to the tooth and tissue surfaces, and host responses to them. In these dysbiotic diseases, damage to the supporting tissues of the teeth occurs because the immune system fails to control both the microbial communities and the local host immune response to them [24].

The term, periodontal disease, describes a spectrum of inflammatory conditions. Gingivitis is an inflammatory response to the accumulation of dental plaque at the gingival margin (Figure). It is reversible and can be eradicated by maintaining good oral hygiene. Conversely, the damage associated with periodontitis is irreversible; chronic inflammation within the supporting tissues of the teeth (Figure) and the consequent tissue destruction and
gingival epithelial migration cause progressive attachment loss and bone loss, characterised by periodontal pocket formation and/or gingival recession [25].

The most common form of periodontitis is chronic adult periodontitis, which is assessed as mild, moderate or severe/advanced depending on the extent of BOP, periodontal pocket formation, radiographic bone loss and CAL [25]. Aggressive periodontitis is a less common, severe form of the disease which often occurs in people under 25 years. It may be localised to certain teeth or generalised, and can be associated with a more sparse plaque than that observed in chronic adult periodontitis. Two RA-associated genes that function in Interferon-β (IFN-β) signalling were highlighted in cases of aggressive periodontitis as shared susceptibility factors, but the aetiologies of aggressive and chronic periodontitis differ and the genetic contribution may be lesser in chronic periodontitis [26, 27].

**The microbiology of periodontal diseases**

Periodontal pockets can reach a probing depth of up to 12mm; this stagnant and anaerobic site may harbour up to $10^8$ diverse bacteria [28]. More than 700 bacterial species have been identified from the human mouth; only about 60% of these can currently be cultured in the laboratory [29], so nucleic acid based methodologies are essential to understand the entirety of the health and disease-associated microbiota. It is important to recognise that periodontitis is a polymicrobial infection caused by co-operating consortia of organisms [30]. Organisms associated with severe periodontitis are often also isolated from healthy sites, albeit in low numbers; pathogenic communities arise from the normal microbiota through processes of selection in response to local environmental pressures that are associated with inflammation and bleeding, and through the failure of the host responses to control the subgingival microbiota [31, 32]. As periodontitis develops, there is a transition from plaque
dominated by Gram-positive facultatively anaerobic species, to communities that are
dominated by obligately anaerobic, proteolytic Gram-negative rods and spirochaetes [32].
Many organisms increase in abundance with the development of periodontitis, and newly
described potential pathogens are emerging [32, 33]. Porphyromonas gingivalis may
function as a “keystone pathogen” in chronic periodontitis, playing a disproportionately
important role by depressing and deregulating local immune responses, increasing the
virulence of the whole community and promoting the dysbiosis that is characteristic of
periodontitis [30]. It is in turn dependent on the activities of accompanying accessory
organisms (e.g. Streptococcus gordonii) to express its full pathogenicity [34].
Aggregatibacter actinomycetemcomitans is associated with localised aggressive periodontitis
(LAP), in which it may function as a keystone pathogen [35, 36]; a combination of A.
actinomycetemcomitans, Filifactor alocis and Streptococcus parasanguinis was highly
predictive of bone loss in individuals susceptible to LAP [35]. Viruses are only rarely
considered, but they may also play a role in development of periodontitis [37].
Oral host-microbe homeostasis is maintained by the constant control of the microbial burden
and protection mediated by inflammatory and immune defences. Periodontal pathogens
manipulate, dysregulate and subvert these defence mechanisms, disabling protective
mechanisms and disrupting control of the microbiota. Inflammophilic species, such as P.
gingivalis, dysregulate processes to drive inflammation and elicit tissue damage, yielding a
supply of nutrients to support their survival.

**The roles of host defences**

Both innate and adaptive immune functions are important to the development of periodontitis.
It is beyond the scope of this review to discuss all immune contributions to the disease in
detail but they have been extensively reviewed recently [38, 39].
The chronic nature of inflammation in periodontitis allows for substantial lymphocyte involvement, including significant B and CD4+ T cell infiltration into gingival tissues and increased expression of Th1 and Th17 cytokines and receptor activator of nuclear factor κ-B ligand (RANKL). RANKL stimulates osteoclastogenesis and subsequent resorption of alveolar bone [39, 40]. Expression of genes encoding IL-1β, IL-6, IL-21 (supporting Th17 differentiation) have been detected in diseased gingival tissue, in addition to IL-23-producing macrophages that amplify Th17 responses [40]. Increases in Th17 cells in the synovium of RA joints have also been reported [39]. In periodontitis, elevated IL-17 levels may perpetuate phagocyte recruitment and induce osteoclastic differentiation of monocytes [38, 40, 41]. A counterbalance to Th1 and Th17 CD4 T cell activity may be provided by CD4 TReg cells, by secretion of immunosuppressive IL-10 and TGF-β, but evidence for the role of IL-10 in periodontal health/disease is equivocal [40].

Innate immunity is involved from the early stages of periodontal disease. Some periodontal bacteria dysregulate the functions of Toll-like receptors (TLRs) expressed by cells in gingival tissues, leading to tissue damage and periodontal disease pathogenesis [24]. Complement is vital, both early in the development of dysbiosis and in driving the inflammatory destruction of periodontal tissue, and the alternative pathway of complement activation predominates in periodontitis [42]. Some bacteria (e.g. P. gingivalis, F. alocis, Prevotella intermedia, Treponema denticola, Tannerella forsythia) manipulate the complement system, e.g. through binding and/or proteolytic cleavage of endogenous inhibitors, C3 convertase or C5 while allowing release of anaphylatoxin C5a. These strategies allow bacteria to evade complement-mediated microbicidal activities, while promoting inflammation and neutrophil recruitment to the periodontal pocket.

Neutrophils are of primary importance in the maintenance of gingival homeostasis [43]. In health, resident bacteria stimulate gingival epithelial cells to establish a CXCL-8 chemotactic
gradient and upregulate expression of the neutrophil chemotactic receptor, CXCR-2, thereby
promoting neutrophil homing to periodontal tissue and their formation into a protective barrier
between the biofilm and host [44]. Neutrophils account for 90% of the leucocytes in gingival
crevicular fluid (GCF) and their concentration increases 15-fold in periodontally diseased
sites [45]. Their fundamental protective role is illustrated by the often severe periodontitis
associated with iatrogenic neutropenia and with inherited dysfunctions in neutrophil effector
functions, e.g. Chediak-Higashi and Papillon Lefevre syndromes. Impaired neutrophil
chemotaxis has been reported in periodontitis and periodontal pathogens employ various
strategies to disrupt neutrophil chemotaxis and/or function [39, 42, 46].

The neutrophil antimicrobial arsenal includes the generation of reactive oxygen species
(ROS), the release of granule contents which include matrix metalloproteinase 8, gelatinases,
myeloperoxidase (MPO), neutrophil serine proteases and antimicrobial peptides such as
α-defensins and hCAP-18 (the LL-37 precursor). Neutrophils generate Neutrophil
Extracellular Traps (NETs), decondensed webs of chromatin that are decorated with
antimicrobial proteins derived from neutrophil granules. A widely held view is that NET
generation is facilitated by NADPH oxidase, neutrophil elastase and peptidyl arginine
deiminase 4 (PAD4); PAD4 converts positively charged arginine residues within histone
proteins into neutral citrulline, thereby disrupting electrostatic interactions and inducing
chromatin decondensation [46, 47]. Increased NET production, or impeded NET clearance,
may contribute to inflammatory responses as NETs provide an extracellular reservoir of
inflammatory components, such as LL-37, bacterial components, ds-DNA and
hypercitrullinated proteins. PAD4−/− mice are more susceptible to bacterial infections and
NETs have been detected in the GCF from periodontal disease sites in abundance [47].
In addition to their importance in periodontal diseases, neutrophils and periodontal bacteria have been implicated in mechanisms that increase the generation of autoantibodies that are important in the development of RA.

**Autoantibodies in RA and periodontal disease.**

The importance in RA of autoantibodies against proteins that have undergone post-translational modification (PTM) has been extensively reviewed recently [1-3]. Some of these antibodies have also been observed in periodontal tissues and disease [26, 48].

Citrullination, a PTM of arginine, is involved in the formation of hair, skin, myelin sheaths, in NET formation and inflammation, and in cell death [1]. It is mediated by PAD enzymes, of which there are five in humans [49]. Citrullination alters tertiary protein structure and function and may expose previously hidden immune epitopes [50]. Neutrophils are enriched for PADs and calcium-associated hyper-activation of neutrophil PADs leads to hypercitrullination of proteins [49]. However, there is an active debate concerning the methods employed to study NETosis, the roles of PADs and the routes to protein hypercitrullination, with the proposal that exposure of neutrophils to bacterial pore-forming toxins, complement membrane attack complex (MAC) or perforin leads to generation of NET-like structures and a process of leukotoxic hypercitrullination [49].

Serum anti-citrullinated protein antibodies (ACPAs) are present in 70% of RA patients; they are associated with RA progression and may be detectable up to 10 years before the onset of clinical disease [48]. Citrullinated proteins have been detected in periodontal tissues [51, 52] and there are significant associations between ACPA seropositivity and periodontal disease [53, 54]. Therefore, a popular hypothesis is that in genetically susceptible individuals, citrullination associated with periodontitis may cause a localised oral mucosal immune response, which can lead to a systemic ACPA response, followed by synovial inflammation.
and the onset of RA [55]. However, Konig et al. have challenged the hypothesised central role for autoantibodies against citrullinated proteins in the loss of tolerance in RA development, asserting the importance of antibodies against native unmodified proteins as the driving force behind loss of immune tolerance, preceding development of ACPAs [56].

Carbamylation is a non-enzymatic PTM in which cyanate binds to the primary amine of lysine and forms carbamyl groups, generating peptidyl-homocitrulline against which autoantibodies (anti-CarP) are generated [2]. Neutrophil MPO can enhance protein carbamylation by promoting generation of cyanate from thiocyanate [57]. Like citrullination, carbamylation may affect protein function, e.g. carbamylation of immunoglobulin G (IgG) can inhibit classical complement pathway activation [58]. Anti-CarP have been detected in ACPA-negative and ACPA-positive pre-RA and established RA patients [59, 60], and were predictive of the development of RA independently of anti–CCP2 (citrullinated cyclic peptide 2) antibodies [61]. In ACPA-negative patients, anti-CarP antibodies are predictive of a more severe RA disease course [62]. However, there were no significant associations between anti-CarP and RA genetic risk factors or smoking, suggesting anti-CarP antibody formation occurs via different biological mechanisms to ACPA formation [63]. A recent study detected a weak association between ACPA seropositivity and periodontitis but there was none between periodontitis and anti-carP seropositivity [53], although carbamylated proteins were detected in inflamed gingival tissues [48] and MPO was elevated in periodontitis [64, 65].

Antibodies against proteins modified with malondialdehyde-acetaldehyde adducts (MAA) were increased in established RA patients and were associated with ACPA and RF detection [66]. MAA are generated when lipid peroxidation by ROS (produced during oxidative stress and released from neutrophils) forms highly reactive malondialdehyde and acetaldehyde molecules, which modify lysine residues of proteins to generate stable MAA [67].
Preliminary data indicate injection of mice with *P. gingivalis* could increase production of MAA antibodies [68].

**Porphyromonas gingivalis, RA and autoantibody production**

*P. gingivalis* expresses several virulence factors, such as fimbriae, lipopolysaccharide, capsular polysaccharide and cysteine proteases (gingipains). These collectively contribute to its ability to colonise, invade and damage host tissues, and also to degrade and dysregulate local immune responses [43]. The arginine-specific (RgpA and RgpB) and lysine-specific (Kgp) gingipains are crucial for *P. gingivalis* survival and growth in the anaerobic periodontal pocket [69] and they are fundamental to its ability to manipulate host immune responses [70, 71].

*P. gingivalis* also produces a peptidyl-arginine deiminase (PPAD) capable of citrullinating host and bacterial proteins, but which has no sequence homology with human PADs [72]. Unlike human PADs, PPAD preferentially citrullinates terminal arginines and also free arginine, and works best at the slightly alkaline pH that is optimal for *P. gingivalis* growth [72, 73]. Rgp gingipains cleave polypeptide chains at internal arginine residues, generating peptides with terminal arginines that are susceptible to PPAD citrullination [74]. PPAD activity has been detected in GCF from periodontitis patients and at lower levels in healthy controls [75]. It is capable of auto-citrullinating some of its 18 arginine residues [76], although there is evidence that anti-PPAD antibodies are not directed against the citrullinated form of PPAD and that in humans, PPAD is not modified in this manner [77]. PPAD enhances cell invasion by *P. gingivalis* [78] and citrullinates host defence components, such as complement and LL-37, with consequent loss of function [79, 80]. Human fibrinogen and α-enolase, two of the proteins targeted by ACPAs in RA [74], are also PPAD substrates and...
antibodies against auto-citrullinated *P. gingivalis* enolase cross react with human α-enolase autoantibodies [48].

Animal model studies support the hypothesis that *P. gingivalis* is important in the aetiology of RA. *P. gingivalis* expressing PPAD accelerated progression and enhanced severity of collagen-induced arthritis in mice and was associated with higher levels of citrullinated proteins at diseased sites [81]. Exposure to *P. gingivalis* in mice expressing human HLA-DRβ1 impaired resistance to the development of arthritis and induced autoimmune arthritis, and generated increased Th17 cell frequency, systemic cytokine activity and ACPA; both PPAD and the HLA-DR1 restriction were needed to drive ACPA generation [82].

Epidemiological studies of the associations between *P. gingivalis*, PPAD or Rgp and RA (including pre-RA) have been equivocal. DNA from *P. gingivalis* was detected in synovial fluid of RA patients more often than in controls [83] and more often in the GCF of RA patients compared with controls [75]. Although one study found no increase in anti-RgpB antibodies in RA sera [76], another found that anti-RgpB antibody levels were significantly elevated in ACPA-positive RA patients compared with ACPA-negative, and the significant association between anti-RgpB IgG and RA was stronger than that between smoking and RA [84].

There are conflicting data and opinions regarding the relationship of PPAD with RA. Elevated PPAD activity in GCF was not clearly associated with RA even though *P. gingivalis* detection in GCF was [75]. While one study found anti-PPAD antibodies were elevated in RA sera compared with sera from controls [76], another found anti-PPAD antibodies did not correlate with ACPA levels or RA disease activity and levels were decreased in RA patients with PD [77]. Methodological differences have been suggested to account for this discrepancy [85]. A recent study of RA patients on disease-modifying anti-rheumatic drug (DMARD) therapy, found a correlation between anti-PPAD IgG and anti-CCP IgG, both of which were significantly increased in the RA group compared with controls [86]. RA patients
treated with biological DMARDs who had low anti-PPAD IgG titres showed a significantly
greater decrease in RA disease activity score compared with patients with high anti-PPAD
IgG titres, indicating that serum IgG anti-PPAD may be useful as a predictive biomarker for
response to RA therapy [87].

Most studies have focused on patients with established RA; to better understand
pathogenesis and develop therapies it is important to also investigate individuals at risk for
the development of RA. An increased concentration of anti-\textit{P. gingivalis} antibodies has
been reported in individuals at genetic risk of developing RA (some also had RA-related
autoantibodies) [88]. Furthermore, higher anti-RgpB IgG levels were found in the blood of
pre-RA and established RA individuals compared with healthy controls; while ACPA levels
increased with time, anti-RgpB antibody levels did not and they decreased following
diagnosis [89]. In contrast, no association between anti-RgpB and pre-RA was found in a
different study of a Southern European cohort [14]. Importantly, these studies did not
evaluate clinical periodontal status alongside \textit{P. gingivalis} antibody levels. In a recent study
of an early inflammatory arthritis cohort, periodontitis, but not the subgingival presence of \textit{P.
gingivalis}, was more enriched in patients who later progressed to classifiable RA [23].

Similarly, De Smit \textit{et al} concluded that, while there was evidence that periodontal disease
may precede symptomatic RA, there was insufficient evidence to confirm a role specifically
for \textit{P. gingivalis} in disease progression [90].

Thus, while the link between periodontitis and RA is established, the specific roles of \textit{P.
gingivalis} or PPAD are less clear. This could partly be due to strain-to-strain differences,
although it is not yet known if there is any difference in the activity of PPAD from different \textit{P.
gingivalis} strains/genotypes. Five distinct \textit{rgpB} genotypes have been found in clinical \textit{P.
gingivalis} isolates and the activity of the expressed gingipains would impact on that of PPAD [91]. The activities of other bacteria in the subgingival community may also be influential;
although *P. gingivalis* is a “keystone pathogen” that increases the risk of periodontitis, it depends upon the activities of other members of the microbiota to colonise, grow, invade epithelial cells and express its full virulence [34].

**Multiple mechanisms may be important**

Periodontitis is a complex disease, mediated by consortia of co-operating bacteria and the host responses to them. It is, therefore, logical to widen consideration of the influence of the microbiota beyond that of a single, albeit important, bacterium. For example, the leukotoxin produced by *A. actinomycetemcomitans* has been implicated in inducing leukotoxic hypercitrullination, and exposure to *A. actinomycetemcomitans* was associated with ACPA and rheumatoid factor (RF) [92]. The subgingival microbiota of periodontitis is enriched for obligately anaerobic proteolytic bacteria [32] and they may contribute alongside *P. gingivalis* to the enzymatic cleavage of host proteins, particularly components of the extracellular matrix, and enhanced generation of neo-epitopes [93, 94]. Using 16S rRNA sequence analysis of the entire subgingival microbiome, Scher *et al.* found that the microbiome of RA patients was similar to healthy subjects with similar periodontal status, but, specific *Prevotella* and *Leptotrichia* operational taxonomic units (OTUs) were only found in new-onset RA patients, and *Anaeroglobus geminatus* was correlated with the presence of ACPA and RF, and with periodontitis [95]. Another large-scale study using metagenomic shotgun sequencing identified compositional and functional alterations in RA-associated oral microbiomes, which were partly resolved by DMARD treatment; thus, this big data approach suggests that microbiome composition could be important in prognosis and diagnosis of RA [96].

Neutrophils are key players in both RA and periodontitis. They can promote autoantibody production by multiple routes, all of which may be important in RA, and they also contribute to the immune dysregulation and tissue damage associated with periodontitis. Interference
with the normal functions of neutrophils is an important pathogenic strategy employed by many periodontal bacteria and some of these may in turn promote neutrophil mediated autoantibody production; e.g. the pore-forming leukotoxin of *A. actinomycetemcomitans* [49]; *F. alocis* promotion of neutrophil degranulation [97]; *P. gingivalis, A. actinomycetemcomitans* and *F. nucleatum* triggering the release of NETs [47].

While local responses are important, systemic influences on blood should be considered. Peripheral blood neutrophils in patients with inflammatory diseases such as periodontitis and RA have been reported to display an activated phenotype with hyperactive respiratory burst responses and, in RA, increased NETosis [47, 98, 99]. Oral bacteria regularly gain access to the blood and have been detected at distant sites such as the heart and also in synovial tissue samples [100]. Pretorius et al. have proposed that an aberrant blood microbiome may play a significant role in the aetiology of RA [101] and other systemic diseases that have been linked to periodontitis [102]. Microscopic analysis of blood from periodontitis patients revealed bacteria associated with erythrocytes at a much higher prevalence than seen in blood from healthy controls [102]. In this analysis, bacteria that gain ingress into the blood may remain dormant, most likely because they are deprived of essential iron; dormant bacteria are associated with circulating cells including erythrocytes and in this state they may constitute a persistent supply of inflammatory molecules including lipopolysaccharide. The authors propose this may be a unifying principle underlying the links between inflammatory diseases such as periodontitis and a range of systemic diseases including RA.

**Practice points:**

The association between RA and periodontitis indicates the potential benefits of the closer integration of medical and dental care:
RA patients have an increased prevalence of periodontal disease and therefore should be encouraged to have regular dental assessments.

Periodontal disease may be associated with increased RA disease activity; if periodontal disease is identified in a patient with RA it should be managed by a dentist.

Individuals at heightened risk for RA (e.g. first degree relatives of RA patients) may benefit from regular dental assessments and early treatment of periodontal disease, in addition to other lifestyle interventions (e.g. smoking cessation).

**Research agenda:**

It is essential to fully understand the pathophysiology of both RA and periodontitis to understand the inter-relationship between the two diseases and to find novel predictive markers of RA disease activity and progression. Some individual organisms such as *P. gingivalis* and *A. actinomycetemcomitans* are important but it is essential to consider the roles of imbalances of the composition and functions of the entire subgingival microbiome and, potentially, the blood microbiome. Further fundamental and translational research is required:

- To determine the influence of periodontal disease on the initiation and propagation of RA-autoimmunity. This will be best investigated in prospective cohorts of at-risk individuals including those with genetic risk (FDRs) and those with systemic autoimmunity.

- To better understand the role of specific organisms such as *P. gingivalis* and *A. actinomycetemcomitans* as well as the entire subgingival microbiome in the development of localized and systemic RA-autoimmunity. To determine which organisms are associated with progression along the continuum from Pre-RA to established RA.
To determine whether periodontal treatment should be considered as an adjunct to immunotherapy in patients with early RA.

To conduct clinical trials to address whether treatment of periodontal disease and/or manipulation of the subgingival microbiome can delay or prevent RA in at-risk individuals.

Summary

Multiple studies have shown an epidemiological association between periodontitis and RA. Specific periodontal pathogens, *P. gingivalis* or *A. actinomycetemcomitans*, have been hypothesised to be of particular importance because they possess virulence determinants (PPAD and leukotoxin, respectively) that can contribute to the generation of citrullinated proteins and potentially trigger development of RA-related autoantibodies. However, periodontitis is a complex disease, mediated by consortia of co-operating bacteria and the host responses to them. Multiple mechanisms are likely to contribute to the association between periodontitis and RA and it is essential to consider the roles of imbalances of the composition and functions of the entire subgingival microbiome. Subgingival bacteria may contribute directly through enzymatic modification of proteins and subsequent autoantibody generation, or indirectly by dysregulation of neutrophils and enhancement of those neutrophil activities that contribute both to neo-epitope generation and host-mediated damage to periodontal tissues. It is possible that periodontal bacteria in the blood and hyper-active peripheral blood neutrophils may play a part in loss of immune tolerance and development of RA. Understanding the mechanisms underlying the inter-relationship between the two diseases and the influence of periodontitis and the periodontal microbiome on the initiation and propagation of RA-autoimmunity may help to identify novel predictive markers in individuals at risk of RA; it will inform clinical trials to determine if periodontal therapy should
be considered as an adjunct to immunotherapy in patients with early RA and whether
treatment of periodontal disease and/or manipulation of the subgingival microbiome can
delay or prevent RA in at-risk individuals.

References


*[19] Fuggle NR, Smith TO, Kaul A, Sofat N. Hand to mouth: A systematic review and meta-analysis of the association between rheumatoid arthritis and periodontitis. Front


for IL-17A and IL-17E in periodontal immunity. Inflamm Res 2014;63:1001-12.


514 [51] Harvey GP, Fitzsimmons TR, Dhamarpatni AASSK, Marchant C, Haynes DR, Bartold PM. Expression of peptidylarginine deiminase-2 and -4, citrullinated proteins and anti-citrullinated


protein antibodies are present prior to rheumatoid arthritis and are associated with its future


Anti-carbamylated protein antibodies are present in arthralgia patients and predict the


Autoantibodies recognizing carbamylated proteins are present in sera of patients with

antibodies in two large cohorts of patients with rheumatoid arthritis and their relationship to
 genetic risk factors, cigarette smoking and other autoantibodies. Ann Rheum Dis

[64] Nizam N, Gumus P, Pitkanen J, Tervahartiala T, Sorsa T, Buduneli N. Serum and salivary
matrix metalloproteinases, neutrophil elastase, myeloperoxidase in patients with chronic or

[65] Leppilahti JM, Hernandez-Rios PA, Gamonal JA, Tervahartiala T, Brignardello-Petersen
R, Mantyla P, et al. Matrix metalloproteinases and myeloperoxidase in gingival crevicular fluid
provide site-specific diagnostic value for chronic periodontitis. J Clin Periodontol
2014;41:348-56.


Malondialdehyde-acetaldehyde adducts and anti-malondialdehyde-acetaldehyde antibodies

*[67] Darrah E, Andrade F. Citrullination, and carbamylation, and
malondialdehyde-acetaldehyde! Oh My! Entering the forest of autoantigen modifications in

malondialdehyde-acetaldhyde adducts are increased in the serum of mice following infection with *P. gingivalis* and/or injection of citrullinated mouse type II collagen: a model of human disease response. *Arthritis Rheum* 2015;67:2.


[93] Sofat N, Wait R, Robertson SD, Baines DL, Baker EH. Interaction between extracellular matrix molecules and microbial pathogens: evidence for the missing link in autoimmunity with


